Balyasny Asset Management
OMED

Balyasny Asset Management’s OncoMed Pharmaceuticals, Inc. OMED Stock Holding History

Balyasny Asset Management’s Portfolio OMED Stock Details OMED Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-175,895
Closed -$3.96M – 1742
2015
Q4 		$3.96M Buy
+175,895
New +$3.6M 0.03% 544

Other funds holding OMED

ASP
Adams Street Partners Chicago, Illinois $260M AUM 30.38% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
IHM
Iguana Healthcare Management New York $152M AUM 48.74% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
DGI
Disciplined Growth Investors Minneapolis, Minnesota $4.89B AUM 33.85% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Balyasny Asset Management's OMED Position: Q1 2016 in Review

Balyasny Asset Management sold out of OncoMed Pharmaceuticals, Inc. (OMED) in Q1 2016, closing a stake of 175,895 shares — an estimated $3.96M sold.

Balyasny Asset Management first reported a position in OMED in Q4 2015 and held it in 1 quarter. The position peaked at $3.96M in Q4 2015. 83 funds tracked by Wall St. Rank hold OMED as of Q1 2016.

  • Balyasny Asset Management reported no remaining OncoMed Pharmaceuticals, Inc. position as of Q1 2016 after selling out during the quarter.
  • Balyasny Asset Management sold 175,895 OncoMed Pharmaceuticals, Inc. shares in Q1 2016, an estimated $3.96M.
  • Balyasny Asset Management first reported a position in OncoMed Pharmaceuticals, Inc. in Q4 2015 and held it in 1 quarter.
  • Balyasny Asset Management's OncoMed Pharmaceuticals, Inc. position peaked at $3.96M in Q4 2015.
  • 83 funds tracked by Wall St. Rank held OncoMed Pharmaceuticals, Inc. as of Q1 2016.

Based on Balyasny Asset Management's 13F filing for Q1 2016, filed 16 May 2016.